Abstract

The therapeutic efficacy of adoptive T cell therapy is largely restricted by reduced viability and dysfunction of CD8+ T cells. Continuous antigen stimulation disrupts the expansion, effector function, and metabolic fitness of CD8+ T cells, leading to their differentiation into an exhausted state within the tumor microenvironment (TME). While the function of the cell cycle negative regulator p16 in senescent cells is well understood, its role in T cell exhaustion remains unclear. In this study, we demonstrated that TCR stimulation of CD8+ T cells rapidly upregulates p16 expression, with its levels positively correlating with TCR affinity. Chronic TCR stimulation further increased p16 expression, leading to CD8+ T cell apoptosis and exhaustion differentiation, without inducing DNA damage or cell senescence. Mechanistic investigations revealed that p16 downregulates mTOR, glycolysis, and oxidative phosphorylation (OXPHOS) associated gene expression, resulting in impaired mitochondrial fitness, reduced T cell viability, and diminished effector function. Furthermore, the deletion of p16 significantly enhances the persistence of CD8+ T cells within tumors and suppresses the terminal exhaustion of tumor-infiltrating T cells. Overall, our findings elucidate how increased p16 expression reshapes T cell intracellular metabolism, drives T cell apoptosis and exhaustion differentiation, and ultimately impairs T cell anti-tumor function.

Details

Title
The cell cycle regulator p16 promotes tumor infiltrated CD8+ T cell exhaustion and apoptosis
Author
Zhang, Xin 1 ; Wang, Jiajia 2 ; Tang, Kun 3 ; Yang, Yu 4 ; Liu, Xiaowei 2 ; Yuan, Shengtao 5 ; Guo, Feng 6 ; Zhang, Lianjun 2   VIAFID ORCID Logo  ; Ma, Kaili 2   VIAFID ORCID Logo 

 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); China Pharmaceutical University, Institute of Pharmaceutical Sciences, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839) 
 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Soochow University, Institutes of Biology and Medical Sciences (IBMS), Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694) 
 Chinese Academy of Medical Sciences & Peking Union Medical College, National Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Synthetic Biology Regulatory Element, Suzhou Institute of Systems Medicine, Suzhou, China (GRID:grid.506261.6) (ISNI:0000 0001 0706 7839); The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Oncology, Suzhou, China (GRID:grid.452511.6) 
 China Pharmaceutical University, Institute of Pharmaceutical Sciences, Nanjing, China (GRID:grid.254147.1) (ISNI:0000 0000 9776 7793) 
 The Affiliated Suzhou Hospital of Nanjing Medical University, Department of Oncology, Suzhou, China (GRID:grid.452511.6) 
Pages
339
Publication year
2024
Publication date
May 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3055244877
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.